Brain metastasis in melanoma: Clinical activity of CTLA-4 antibody therapy

Seminars in Oncology

Volumn 37, Issue 5, 2010, Pages 468-472

  Margolin, Kim A ^a   Di Giacomo, Anna Maria ^b   Maio, Michele ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; FOTEMUSTINE; GLUCOCORTICOID; INTERLEUKIN 2; IPILIMUMAB; TEMOZOLOMIDE;

ASTHENIA; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CEREBROSPINAL FLUID; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EUROPE; HUMAN; IMMUNOMODULATION; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SEIZURE; SINGLE DRUG DOSE; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR IMMUNITY; UNITED STATES; VOMITING;

EID: 78449260943     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.09.014     Document Type: Article

References (30)

1. K. Margolin, G. Cannon, and M. Mehta Multidisciplinary management of CNS melanoma metastases C.M. Balch, Cutaneous melanoma Ed 5 2009 Quality Medical Publishing St Louis, MO 651 665
2. Zakrzewski J, Geraghty L, Rose A, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastasis and post-brain metastasis survival. Cancer. In press.
3. Eigentler TK, Figl A, Krex D, et al. Number of metastases, serum LDH-level and kind of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. In press.
4. Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. In press.
5. J.H. Sampson, J.H. Carter, and A.H. Friedman Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma J Neurosurg 88 1998 11 20
6. K.M. Fife, M.H. Colman, and G.N. Stevens Determinants of outcome in melanoma patients with cerebral metastases J Clin Oncol 22 2004 1293 1300
7. S. Meier, B.G. Baumert, and T. Maier Survival and prognostic factors in patients with brain metastases from malignant melanoma Onkologie 27 2004 145 149
8. M. Staudt, K. Lasithiotakis, and U. Leiter Determinants of survival in patients with brain metastases from cutaneous melanoma Br J Cancer 102 2010 1213 1218
9. D.N. Liew, H. Kano, and D. Kondziolka Outcome predictors of gamma knife surgery for melanoma brain metastases J Neurosurg June 4, 2010 Epub ahead of print: DOI: 10.3171/2010.5.JNS1014
10. A. Stone, J. Cooper, and K.L. Koenig A comparison of survival rates for treatment of melanoma metastatic to the brain Cancer Invest 22 2004 643 644
11. M. Majer, R.L. Jensen, and D.C. Shrieve Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases Cancer 110 2007 1329 1337
12. I.J. Fidler, G. Schackert, and R.D. Zhang The biology of melanoma brain metastasis Cancer Metast Rev 18 1999 387 400
13. J. Clarke, N. Butowski, and S. Chang Recent advances in therapy for glioblastoma Arch Neurol 67 2010 279 283
14. K. Margolin, M.B. Atkins, and J.A. Thompson Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group J Cancer Res Clin Oncol 128 2002 214 218
15. M.B. Atkins, J.A. Sosman, and S. Agarwala Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study Cancer 113 2008 2139 2145
16. S.S. Agarwala Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma Melanoma Res 20 2010 1 10
17. F.S. Hodi, and D.E. Fisher Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma Nat Clin Pract Oncol 12 2008 696 697
18. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
19. N.E. Schartz, C. Farges, and I. Madelaine Complete regression of a previously untreated melanoma brain metastasis with ipilimumab Melanoma Res 20 2010 247 250
20. F.S. Hodi, D.A. Oble, and J. Drappatz CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS Nat Clin Pract Oncol 5 2008 557 561
21. M.F. Avril, S. Aamdal, and J.J. Grob Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study J Clin Oncol 22 2004 1118 1125
22. M. Maio, E. Fonsatti, and A. Burigo The Italian Network for Tumor Biotherapy (NIBIT): sharing visions, goals and efforts at European level Tumori 94 2008 179 181
23. Trial NIBIT-M1 http://oss-sper-clin.agenziafarmaco.it/cgi-bin/ossc-index- pub?FILE=area-PUB-new
24. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
25. K.C. Kaehler, S. Piel, and E. Livingstone Update on immunologic therapy with anti-CTLA4 antibodies in melanoma: identification of clinical and biological response patterns, immune related adverse events and their management Semin Oncol 37 2010 485 498
26. M.K. Callahan, J.D. Wolchok, and J.P. Allison Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy Semin Oncol 37 2010 473 484
27. D. Berman, J.D. Wolchok, and J. Weber Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (patients) with advanced melanoma treated with ipilimumab [abstract] J Clin Oncol 27 2009 3020
28. G.Y. Ku, J. Yuan, and D.B. Page Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting Cancer 116 2010 1767 1775
29. Di Giacomo AM, Danielli R, Calabr L, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Submitted.
30. A.M. Di Giacomo, M. Biagioli, and M. Maio The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications Semin Oncol 37 2010 499 507